Endocrine treatment of cancer

Journal of the Royal Society of Medicine

Volumn 89, Issue 8, 1996, Pages 448-453

  Gulliford, Tim ^a   Epstein, Richard J ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR PROTEIN;

CANCER; CELL DEATH; CLINICAL OBSERVATION; HORMONAL THERAPY; HUMAN; LYSIS; MOLECULAR BIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029793303     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107689608900808     Document Type: Review

References (32)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;ii:104-7, 162-5
2. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg R, Touw IP. Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995;333:487-93
3. Komminoth P, Kunz EK, Matias-Guiu X, et al. Analysis of RET protoonocogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 1995;76:479-89
4. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992;89:6319-23
5. Taplin M, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8
6. Karnik PS, Kulkarni S, Liu X, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-53
7. Fuqua S, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995;35:233-41
8. Ottaviano YL, Issa J, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-5
9. Maton PN. The use of the long-acting somatostatin analogue, octreotide, in patients with islet-cell tumors. Gastroenterol Clin N Am 1989;18:897-922
10. Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993;90;786-9
11. Brandstrom A, Westin P, Bergh A, Cajander S, Damber J. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res 1994;54: 3594-601
12. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53
13. Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 1992;89:11538-42
14. Ma ZQ, Spreafico E, Pollio G, et al. Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci USA 1993;90:3740-44
15. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;442:1589-93
16. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981;5:39-44
17. Cooper DS. Thyroxine suppression therapy for benign nodular disease. J Clin Endoc Metab 1995;80:331-5
18. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85
19. Scottish Cancer Trials Office and ICRF Breast Unit. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993;341:1293-8
20. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-52
21. Graham SD, Keane TE, Petros JA, Sanders WH. Perioperative hormonal therapy in locally advanced adenocarcinoma of the prostate. Cancer 1995;75:1969-71
22. Henderson IC. Endocrine therapy in metastatic breast cancer. In: Harris J, Hellman S, Henderson I, Kinne D, eds. Breast Diseases. Philadelphia: JB Lippincott, 1987:398-428
23. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9
24. Epstein RJ. The clinical biology of hormone-responsive breast cancer. Cancer Treat Rev 1988;15:33-51
25. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 1993;71:2782-90
26. Klotz LH, Herr HW, Morse MJ, et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:46-50
27. Mortel R, Levy C, Wolff JC, et al. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res 1981;41:1140-7
28. Pandya KJ, Yeap BY, Davis TE. Phase II study of megestrol and mepestrol and tamoxifen in advanced endometrial carcinoma: an Eastern Cooperative Oncology Group study [Abstract]. Proc Am Assoc Cancer Res 1989;30:A1037
29. Carlson JJ, Allegra JC, Day TJ, Wittliff JL. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 1984;149:149-53
30. Sainsbury JRC, Sherbet GV, Farndon JR, Harris AL. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985;i:364-6
31. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7
32. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8